On Thursday, Cathie Wood-led Ark Invest made notable trades involving Advanced Micro Devices Inc. and Tempus AI Inc.. These trades reflect Ark’s strategic repositioning amid evolving market dynamics.

The AMD Trade

ARK Innovation ETF fund reduced its stake in Advanced Micro Devices Inc. by selling 8,045 shares. The transaction, valued at approximately $3.3 million, was executed at AMD’s closing price of $408.46 on Thursday.

This move aligns with Ark’s recent trend of trimming its AMD holdings. Recently, AMD’s CEO, Lisa Su, highlighted the company’s strong start to 2026, driven by increased AI adoption and demand for compute infrastructure. The rise of AI agents has significantly boosted the need for CPUs, despite the critical role of GPUs in AI acceleration.

Despite the positive outlook, Ark’s decision to sell AMD shares may indicate a strategic shift. The company has been capitalizing on AMD’s recent performance, as the stock has been hot due to the AI-driven demand surge. On Tuesday, Ark sold $16 million worth of AMD shares, while on Wednesday the firm offloaded stock worth $8 million. AMD stock has shot up over 16% in the last 5 days.

The Tempus AI Trade

In contrast, Ark Invest increased its position in Tempus AI Inc. by acquiring a total of 154,045 shares across its ARK Genomic Revolution ETF and ARKK funds. The purchase, valued at approximately $7.7 million, was made at Tempus AI’s closing price of $49.47.

Tempus AI recently reported a 36.1% rise in first-quarter revenue, driven by strong demand for its oncology diagnostics and AI-driven data business. The company exceeded analyst expectations with quarterly revenue reaching $348.1 million. Despite widening net losses, Tempus AI raised its full-year revenue outlook, signaling confidence in its growth trajectory.

This strategic investment by Ark reflects confidence in Tempus AI’s potential, particularly given its impressive revenue growth and market position. The company’s diagnostics revenue saw a 34.7% increase, while its data and applications revenue climbed 40.5% to $87 million, underscoring its robust performance in the AI sector.

Ark purchased $7.8 million worth of Tempus AI stock on Thursday.

Other Key Trades:

• Sold 44,291 shares of CareDx Inc. from ARKG.

• Sold 33,134 shares of Adaptive Biotechnologies Corp. from ARKG.

• Bought 102,247 shares of Intellia Therapeutics Inc. in ARKK.

• Sold 9,210 shares of Teradyne Inc. from ARKK.